| scholarly article | Q13442814 |
| P50 | author | Daniel Globisch | Q30503857 |
| P2093 | author name string | Ian A Wilson | |
| Joel E Schlosburg | |||
| Kim D Janda | |||
| Lisa M Eubanks | |||
| Jenny M Lively | |||
| Karen C Collins | |||
| Jonathan W Lockner | |||
| Jennifer L Choi | |||
| Robin J Rosenfeld-Gunn | |||
| P2860 | cites work | Structural basis of TLR5-flagellin recognition and signaling | Q24628830 |
| Conformational change of flagellin for polymorphic supercoiling of the flagellar filament | Q27660232 | ||
| Comparative protein modelling by satisfaction of spatial restraints | Q27860866 | ||
| The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 | Q28185796 | ||
| Vaccine pharmacotherapy for the treatment of cocaine dependence | Q28263232 | ||
| Identity of tumour necrosis factor and the macrophage-secreted factor cachectin | Q28286678 | ||
| Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice | Q28743887 | ||
| Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats | Q29619737 | ||
| A thermostable bacterial cocaine esterase rapidly eliminates cocaine from brain in nonhuman primates | Q30054735 | ||
| Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults | Q30395173 | ||
| Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections | Q30421519 | ||
| Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans | Q30427490 | ||
| Crystallization of the F41 fragment of flagellin and data collection from extremely thin crystals | Q30626209 | ||
| Phage-displayed random peptide libraries in mice: toxicity after serial panning | Q33184744 | ||
| Vaccines against stimulants: cocaine and MA | Q33582086 | ||
| High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation | Q33591155 | ||
| Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors | Q33591916 | ||
| Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial | Q33883669 | ||
| A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice | Q33905188 | ||
| Comparison of inflammation, organ damage, and oxidant stress induced by Salmonella enterica serovar Muenchen flagellin and serovar Enteritidis lipopolysaccharide | Q34116277 | ||
| The future potential for cocaine vaccines | Q34132804 | ||
| Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects | Q34216479 | ||
| Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis | Q34334406 | ||
| Antibodies against Marinobacter algicola and Salmonella typhimurium flagellins do not cross-neutralize TLR5 activation | Q34478993 | ||
| The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. | Q34618662 | ||
| Immunopharmacotherapeutic manifolds and modulation of cocaine overdose | Q34754121 | ||
| Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. | Q34760675 | ||
| Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. | Q35139384 | ||
| Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis | Q35272921 | ||
| Vaccines against drug abuse | Q35938624 | ||
| Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus | Q36014803 | ||
| Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. | Q36562614 | ||
| Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse mo | Q36911461 | ||
| Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design | Q36951455 | ||
| Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates | Q37051021 | ||
| Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy | Q37052393 | ||
| Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse | Q37082158 | ||
| Flagellin as an adjuvant: cellular mechanisms and potential. | Q37130379 | ||
| Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin | Q37164038 | ||
| Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. | Q37172714 | ||
| Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. | Q37497786 | ||
| Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway | Q37587048 | ||
| Probing the effects of hapten stability on cocaine vaccine immunogenicity | Q37624530 | ||
| Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy | Q37714150 | ||
| Targeting Toll-like receptors: emerging therapeutics? | Q37727910 | ||
| Use of defined TLR ligands as adjuvants within human vaccines. | Q37825528 | ||
| Pharmacological treatments for cocaine dependence: is there something new? | Q37869526 | ||
| Metabolic responses to cachectin/TNF. A brief review | Q37936351 | ||
| Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants | Q37981769 | ||
| Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. | Q38030027 | ||
| Modern subunit vaccines: development, components, and research opportunities | Q38073752 | ||
| Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. | Q38678908 | ||
| Efficient delivery of the toll-like receptor agonists polyinosinic:polycytidylic acid and CpG to macrophages by acetalated dextran microparticles. | Q39139592 | ||
| Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses | Q39398295 | ||
| The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. | Q39473693 | ||
| Demonstration of two types of helper T cells for different IgG subclass responses to dinitrophenylated flagellin polymer | Q39484155 | ||
| TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin | Q39632623 | ||
| Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults | Q39744811 | ||
| A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity | Q40138835 | ||
| Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity | Q40232989 | ||
| Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses | Q40763973 | ||
| A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. | Q43121719 | ||
| Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization | Q43502929 | ||
| Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response | Q44237462 | ||
| Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants | Q44927749 | ||
| Escherichia coli-based cell free production of flagellin and ordered flagellin display on virus-like particles | Q45352060 | ||
| Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant | Q46523290 | ||
| Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza | Q46910691 | ||
| Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response | Q47578800 | ||
| Soluble flagellin, FliC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella typhimurium infection. | Q50042606 | ||
| Flagellin treatment protects against chemicals, bacteria, viruses, and radiation | Q50061502 | ||
| Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction | Q50117610 | ||
| Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. | Q50583511 | ||
| Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). | Q54361083 | ||
| Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo | Q56904232 | ||
| Removal of endotoxin from protein solutions by phase separation using Triton X-114 | Q68480102 | ||
| Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses | Q69301356 | ||
| A fluorescence-based protein assay for use with a microplate reader | Q72631425 | ||
| Oil-in-water liposomal emulsions for vaccine delivery | Q75234093 | ||
| Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin | Q80155644 | ||
| TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha | Q80481070 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 653-662 | |
| P577 | publication date | 2015-01-07 | |
| P1433 | published in | Molecular Pharmaceutics | Q3011140 |
| P1476 | title | Flagellin as carrier and adjuvant in cocaine vaccine development | |
| P478 | volume | 12 |
| Q47273296 | Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination |
| Q38634734 | Bacterial flagellin-a potent immunomodulatory agent. |
| Q39576940 | Biologics to treat substance use disorders: Current status and new directions |
| Q46146258 | Cocaine Vaccine Development: Evaluation of Carrier and Adjuvant Combinations That Activate Multiple Toll-Like Receptors |
| Q53074356 | Crystal structure of Bacillus cereus flagellin and structure-guided fusion-protein designs. |
| Q43076031 | Current status and future prospects for the development of substance abuse vaccines. |
| Q93374969 | Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin |
| Q58087139 | Lateral Flow Assessment and Unanticipated Toxicity of Kratom |
| Q35917088 | Linear antigenic mapping of flagellin (FliC) from Salmonella enterica serovar Enteritidis with yeast surface expression system |
| Q100992530 | Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders |
| Q58580396 | Novel Chimeric Protein Vaccines Against Infection |
Search more.